1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Supplier
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY TYPE
5.1. Introduction
5.2. Generics
5.3. Orphan Drugs
5.4. Others
6. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY APPLICATION
6.1. Introduction
6.2. Diabetes
6.3. Oncology
6.4. Cardiovascular Diseases
6.5. Autoimmune Diseases
6.6. Others
7. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Drug Stores & Retail Pharmacy
7.4. Online Pharmacy
8. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. UK
8.4.2. Germany
8.4.3. France
8.4.4. Others
8.5. Middle East and Africa
8.5.1. United Arab Emirates
8.5.2. Israel
8.5.3. Saudi Arabia
8.5.4.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Novartis AG
10.2. Pfizer Inc.
10.3. Sanofi
10.4. Johnson & Johnson Services, Inc.
10.5. Merck & Co., Inc.
10.6. AbbVie Inc.
10.7. GlaxoSmithKline plc.
10.8. AstraZeneca
10.9. Bristol-Myers Squibb Company
10.10. Amgen Inc.
10.11. Teva Pharmaceutical Industries Ltd.
10.12. Novo Nordisk A/S
10.13. Bayer AG
10.14. Gilead Sciences, Inc
10.15. Eli Lilly and Company
10.16. Allergan
10.17. Takeda Pharmaceutical Company Limited
10.18. Boehringer Ingelheim International GmbH